Generated by All in One SEO v4.9.9, this is an llms.txt file, used by LLMs to index the site.

# STOP2030

Bringing innovation to intestinal worm treatment

## Sitemaps

- [XML Sitemap](https://stop2030.org/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [A landscape analysis of financing pathways for the ivermectin-albendazole FDC](https://stop2030.org/new-study-maps-financing-challenges-and-opportunities-for-the-ivermectin-albendazole-fdc/) - A new paper in PLOS Neglected Tropical Diseases examines how global health funding patterns can shape access to the novel fixed-dose combination (FDC) of ivermectin and albendazole, the first new soil-transmitted helminth (STH) treatment in decades. Unlike the treatments currently in use, the FDC may not be donated. Co-authored by researchers from Bridges to Development
- [Study maps cost-effectiveness evidence for STH control, supporting community-wide and integrated strategies](https://stop2030.org/study-maps-cost-effectiveness-evidence-for-sth-control-supporting-community-wide-and-integrated-strategies/) - A new scoping review published in PLOS Neglected Tropical Diseases maps the available evidence on the cost-effectiveness of soil-transmitted helminthiasis (STH) control programs, concluding that community-wide and integrated mass drug administration (MDA) strategies consistently outperform school-only approaches in high-prevalence settings. The study, titled Cost-effectiveness of soil-transmitted helminthiasis intervention programmes: A scoping review and conducted as
- [STOP2030 at the Annual NTD Programme Manager Meeting: STH innovation in focus](https://stop2030.org/stop2030-at-the-annual-ntd-programme-manager-meeting-sth-innovation-in-focus/) - Several members of the STOP2030 consortium participated in the 2026 Annual Meeting of NTD Programme Managers in Africa, held in Lilongwe, Malawi, from 13 to 16 April. The meeting, organised under the theme "Leveraging Innovative Tools and Sustainable Financing to Advance NTD Elimination in Africa," is one of the most important gatherings for national NTD
- [Ghana FDA approves the fixed-dose coformulation of ivermectin and albendazole](https://stop2030.org/ghana-fda-approves-the-fixed-dose-coformulation-of-ivermectin-and-albendazole/) - In the last days of December 2025, the Ghana Food and Drug Authority (Ghana FDA) approved the fixed-dose coformulation (FDC) of ivermectin and albendazole. This is a major milestone for the STOP2030 project, and makes Ghana the first country to register the FDC for clinical use. The registration of the FDC in Ghana marks 2025
- [The REALISE clinical begins sample collection and dosing](https://stop2030.org/the-realise-clinical-begins-sample-collection-and-dosing/) - Our latest clinical trial has started its clinical phase as sample collection and dosing started in Kenya
- [Meta-analysis shows age-based fixed ivermectin dosing could transform MDA campaigns](https://stop2030.org/metaanalysis-ivermectin/) - Ivermectin, one of the two medicines used in our fixed-dose co-formulation — together with albendazole — is currently dosed individually, on a weight or height-based basis. This brings several complications to the logistics of mass drug administration (MDA) campaigns, requiring health workers to weigh or measure tens of thousands of people — a slow, complex
- [With the Site Initiation Visit Complete, Our Team Prepares to Launch the REALISE Study](https://stop2030.org/with-the-site-initiation-visit-complete-our-team-prepares-to-launch-the-realise-study/) - The Ghana Health Service (GHS) Research and Development Division, along with the Neglected Tropical Diseases Programme, Mundo Sano, and the Margan Clinical Research Organization, successfully conducted a Site Initiation Visit (SIV) from June 3rd to 6th in Axim and Takoradi (Ghana). This visit is a necessary step before the launch of the clinical trial titled
- [EMA adopts positive scientific opinion on our ivermectin/albendazole fixed-dose coformulation](https://stop2030.org/ema-adopts-positive-scientific-opinion-on-our-ivermectin-albendazole-fixed-dose-coformulation/) - The STOP2030 Consortium is pleased to announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive scientific opinion for the fixed-dose combination (FDC) of albendazole and ivermectin for soil-transmitted helminths and lymphatic filariasis infections for adult, teenagers and children aged 5 years and older.
- [Our FDC of albendazole & ivermectin demonstrates safety and superior efficacy in phase 2-3 trial](https://stop2030.org/fdc-safety-superior-efficacy-phase-2-3-clinical-trial/) - Researchers from African, Latin American and European organisations have published the results of the ALIVE study, the phase 2/3 pivotal clinical trial that demonstrates the safety and superior efficacy of our fixed-dose coformulation (FDC) of albendazole and ivermectin in the control of soil-transmitted helminths (STH). The study was successfully carried out by the STOP 1
- [STOP2030 team at InCORNTD 2025](https://stop2030.org/stop2030-incorntd-2025/) - Colleagues from the STOP2030 consortium attended last week the International Conference for Research on NTDs (InCORNTD) 2025 in Kigali, Rwanda. This annual conference brought together leading voices in the fight against neglected tropical diseases (NTDs), including researchers, policymakers, global health organizations, and innovators. It served as a powerful platform for exchanging ideas and advancing solutions
- [Our latest popPK study supports the dosing strategy of our ivermectin/albendazole FDC](https://stop2030.org/our-latest-poppk-study-supports-the-dosing-strategy-of-our-ivermectin-albendazole-fdc/) - A new paper on the population pharmacokinetics (PK) of our fixed-dose combination (FDC) is out. Building on data collected from children, adolescents and adults, both healthy and infected with soil-transmitted helminths (STH), a study led by Jaime Algorta (Liconsa, part of the STOP2030 consortium) shows that the FDC dosages (400mg/9mg and 400mg/18mg of albendazole and
- [WHO Publishes the First Guidelines for Controlling Strongyloides stercoralis](https://stop2030.org/controlling-strongyloides-blog/) - Controlling Strongyloides stercoralis: WHO's recommendations for addressing it as a public health issue Strongyloides stercoralis is one of the most challenging soil-transmitted helminth (STH) species to diagnose and control. Although it affects millions of people worldwide, research on this parasite has been limited. This makes the publication of the first WHO guidelines for its
- [ESACIPAC (KEMRI) designated as a WHO Collaborating Centre on NTDs](https://stop2030.org/esacipac-kemri-designated-as-a-who-collaborating-centre-on-ntds/) - The Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC), a part of KEMRI, has been designated as a WHO Collaborating Centre on monitoring and evaluation of neglected tropical diseases (NTDs) for the next four years. As part of their commitment, they will carry out activities to support disease mapping and impact assessment surveys
- [Innovating a 50-Year-Old Drug: The Fixed-Dose Ivermectin Approach](https://stop2030.org/innovating-a-50-year-old-drug-fixed-dose-ivermectin/) - The quest to find optimal treatment strategies for Neglected Tropical Diseases (NTDs) has been ongoing for many years. In the case of Soil-Transmitted Helminthiasis (STH), which involves five different species of intestinal worms and affects more than 1 billion people worldwide, this endeavor is still a work in progress. The World Health Organization’s (WHO)
- [STOP2030 Consortium Gathers in Nairobi to Plan Steps Towards the Finish Line](https://stop2030.org/stop2030-consortium-gathers-in-nairobi-to-plan-steps-towards-the-finish-line/) - On June 5-6, the seven partner organizations within the STOP2030 Consortium met in Nairobi for its Annual Meeting, hosted by the Kenya Medical Research Institute (KEMRI). Over 20 participants from all the teams convened to discuss and decide on the next steps required to advance the fixed-dose combination (FDC) of albendazole and ivermectin towards its
- [Collins Okoyo earned his PhD by modelling the best strategies for the elimination of STH](https://stop2030.org/collins-okoyo-phd-modelling-best-strategies-elimination-sth/) - We are happy to announce that Collins Okoyo, the STOP2030’s lead statistician from KEMRI, successfully defended his doctoral dissertation on April and will graduate as a PhD. His research explores the merits of sanitation and pharmacological strategies against STH
- [The design of our REALISE study is now complete, and public](https://stop2030.org/name-of-the-post-number-three/)
- [STOP2030 welcomes its Scientific & Technical Advisory Board](https://stop2030.org/stop2030-welcomes-its-scientific-technical-advisory-board/) - Our project has taken an important step forward by hosting the first meeting with our newly formed Scientific & Technical Advisory Board (STAB). This meeting marks our commitment to incorporating external expertise and insights that enhance our team’s capabilities and perspectives. By bringing together world-renowned experts, we hope to improve our chances of successfully delivering
- [Promoting WASH measures to combat NTDs](https://stop2030.org/promoting-wash-measures-to-combat-ntds/) - Every 22nd of March we celebrate World Water Day, a time to reflect on the importance of a resource that, while taken for granted by some, remains scarce for a substantial portion of the global population. Even today, 74 million people will have their lives shortened due to diseases related to poor water sanitation and
- [Neglected Women’s Diseases: Addressing the Gender Gap in NTDs](https://stop2030.org/neglected-womens-diseases/) - We live in a world of inequalities. On International Women's Day, we want to address two that intersect: gender inequality and access to healthcare, because, in areas affected by NTDs, women are at a double disadvantage. Neglected Tropical Diseases (NTDs) are a group of diseases caused by a variety of pathogens that affect adults and
- [Uniting for progress: STOP2030 kick-starts collaboration in Madrid](https://stop2030.org/uniting-for-progress-stop2030-kick-starts-collaboration-in-madrid/) - The STOP2030 kick-off meeting held on the 6th and 7th of July at the AC Hotel Cuzco in Madrid marked a significant first step of the project. The partners gathered in person for the first time to discuss the upcoming work and kindle a shared enthusiasm to achieve the project goals. We at STOP2030 have
- [Uniting for progress: STOP2030 kick-starts collaboration in Madrid - fr](https://stop2030.org/fr/uniting-for-progress-stop2030-kick-starts-collaboration-in-madrid-fr/) - The STOP2030 kick-off meeting held on the 6th and 7th of July at the AC Hotel Cuzco in Madrid marked a significant first step of the project. The partners gathered in person for the first time to discuss the upcoming work and kindle a shared enthusiasm to achieve the project goals. We at STOP2030 have
- [Uniting for progress: STOP2030 kick-starts collaboration in Madrid - pt](https://stop2030.org/pt/uniting-for-progress-stop2030-kick-starts-collaboration-in-madrid-pt/) - The STOP2030 kick-off meeting held on the 6th and 7th of July at the AC Hotel Cuzco in Madrid marked a significant first step of the project. The partners gathered in person for the first time to discuss the upcoming work and kindle a shared enthusiasm to achieve the project goals. We at STOP2030 have
- [Uniting for progress: STOP2030 kick-starts collaboration in Madrid - es](https://stop2030.org/es/uniting-for-progress-stop2030-kick-starts-collaboration-in-madrid-es/) - The STOP2030 kick-off meeting held on the 6th and 7th of July at the AC Hotel Cuzco in Madrid marked a significant first step of the project. The partners gathered in person for the first time to discuss the upcoming work and kindle a shared enthusiasm to achieve the project goals. We at STOP2030 have

## Pages

- [Home](https://stop2030.org/) - An international partnership to implement a new two-in-one medicine for helminthiasis
- [Papers](https://stop2030.org/publications/) - The story behind our coformulationThe fixed-dose combination of ivermectin and albendazole is the result of more than 10 years of innovations carried out by African, Latin American and European organizations working in public-private partnership. Here are our main publications, projects and milestones. Explore the timeline of our work and discover how our team is advancing
- [Project](https://stop2030.org/project/) - A unique approach to helminthiasis treatment Unleashing the power of combination Five species, two drugs, one pill An affordable and efficient tool to control infection Our approach at STOP2030 is to combine two existing drugs into a single tablet that allows a more efficient and affordable treatment of helminthic infections. These two compounds are albendazole
- [FAQs](https://stop2030.org/faqs/) - FAQsHow are soil-transmitted helminth infections treated right now? The treatment can vary depending on the species and local regulations. In general terms, benzimidazoles (albendazole and mebendazole) are being used for hookworm (Ancylostoma duodenale and Necator americanus), roundworm (Ascaris lumbricoides) and whipworm (Trichuris trichiura); and ivermectin is recommended for threadworm (Strongyloides stercoralis). In some areas, the
- [Proyecto](https://stop2030.org/es/proyecto/) - Un enfoque único para el tratamiento de las helmintiasis Desatando el poder de la combinación Cinco especies, dos medicamentos, una pastilla Una herramienta asequible y eficiente para controlar la infección Nuestro enfoque en STOP2030 busca combinar dos medicamentos existentes en un solo comprimido que permita un tratamiento más eficiente y asequible de las infecciones helmínticas.
- [Consortium](https://stop2030.org/consortium/) - Meet the partners Research and clinical experts in helminths Click on the pin-points to view the partners Click on the pin-points to view the partners Ghana Ghana Health Service (GHS)Kenya Kenya Medical Research Institute (KEMRI)Spain Laboratorios Liconsa SA (Liconsa)Fundación Mundo Sano (FMS)Fundacion Privada Instituto De Salud Global Barcelona (ISGLOBAL)Switzerland Bridges To Development (Bridges)United Kingdom Wellcome
- [Consorcio](https://stop2030.org/es/consorcio/) - Conoce a los colaboradores Expertos en investigación y clínica de helmintos Click on the pin-points to view the partners Haz clic en los puntos para ver a los colaboradores Ghana Ghana Health Service (GHS)Kenya Kenya Medical Research Institute (KEMRI)Spain Laboratorios Liconsa SA (Liconsa)Fundación Mundo Sano (FMS)Fundacion Privada Instituto De Salud Global Barcelona (ISGLOBAL)Switzerland Bridges To
- [Resources](https://stop2030.org/resources/) - Multimedia resources Explore our available materials Presentation video Other videos ALIVE phase 2/3 trial motion InCORNTD video #MeetThePartners videosMundo Sano Liconsa KEMRI ISGlobal GHS Bridges to Development Wellcome Sanger Institute Printed materials Journey poster Fixed-dose ivermectin poster ALIVE trial results poster downloaddownloaddownloadBrochure downloadPhoto galleryWorld NTD Day Campaigns2024 Our latest research results Explore our publications repository
- [Home-es](https://stop2030.org/es/home-es/) - Innovando en el tratamiento de parásitos intestinales Una colaboración internacional para implementar un nuevo medicamento dos en uno para la helmintiasis El resultado de más de 5 años de investigación La historia detrás de nuestro tratamiento para los parásitos intestinales. El proyecto de investigación STOP2030 marca los pasos finales en nuestro viaje para crear un
- [Background](https://stop2030.org/background/) - Intestinal worms A long history of unmet needs Impacting health and education Five worm species, a quarter of the world’s population infected Soil-transmitted helminths (STH) infections are considered Neglected Tropical Diseases, a group of illnesses that affect children and adults in the world’s poorest communities. There are five main STH species: Ascaris lumbricoides, Trichuris trichiura,
- [Papers (old)](https://stop2030.org/papers/) - A journey through the studies behind STOP2030The development of fixed-dose ivermectin STOP Projects Co-administration of albendazole and ivermectin Registry Fixed-dose ivermectin use for MDA campaigns Exploring the feasibility of fix dose regimens of ivermectin for Mass Drug Administration activities for the control of STH and other NTDs. PROSPERO 2024 2024 Registry REALISE Clinical Trial FDC
- [News](https://stop2030.org/news/) - Latest news Stay up to date with STOP2030 The Bridge Subscribe to our newsletter ‘The Bridge‘, collaboratively made with other EDCTP3 Global Health projects to provide periodic updates on poverty-related diseases control: PDMC Saves Lives NeuroSolve SEMA React STROGHAT eWHORM Name *emailSubscribeProject news A landscape analysis of financing pathways for the ivermectin-albendazole FDCMUND0S4N0_5T0P2026-07-16T11:03:00+00:00July 10, 2026|A
- [FAQs](https://stop2030.org/faqs-es/) - FAQs¿Cómo se tratan actualmente las infecciones por helmintos transmitidos por el suelo? El tratamiento puede variar dependiendo de la especie y las regulaciones locales. En términos generales, se usan benzimidazoles (albendazol y mebendazol) para A. duodenale, N. americanus, A. lumbricoides y T. trichiura; y se recomienda ivermectina para S. stercoralis. En algunas áreas, el tratamiento
- [Contact](https://stop2030.org/contact/) - Contact us Get in touch with our team Recaredo, 3 28002, Madrid (Spain) (+34) 916 50 99 43 communication@stop2030.org Your name *Your email *Your message *He leído el texto informativo / I read the informative text Español: Los datos facilitados serán tratados por Fundación Mundo Sano con el fin de atender y dar respuesta a
- [Contact-fr](https://stop2030.org/fr/contact-fr/) - Contactez-nous Contactez notre équipe Recaredo, 3 28002, Madrid (Spain) (+34) 916 50 99 43 communication@stop2030.org Votre nom et prénom *Votre courriel *Votre message *He leído el texto informativo / I read the informative text Español: Los datos facilitados serán tratados por Fundación Mundo Sano con el fin de atender y dar respuesta a su solicitud,
- [Contato](https://stop2030.org/pt/contato/) - Fale connosco Entre em contacto com a nossa equipa Recaredo, 3 28002, Madrid (Spain) (+34) 916 50 99 43 communication@stop2030.org Nome *E-mail *Mensagem *He leído el texto informativo / I read the informative text Español: Los datos facilitados serán tratados por Fundación Mundo Sano con el fin de atender y dar respuesta a su solicitud,
- [Projet](https://stop2030.org/fr/projet/) - Une approche unique pour le traitement de l’helminthiase Libérer la puissance de la combinaison Cinq espèces, deux médicaments, un comprimé Un outil accessible et efficace pour contrôler l’infection L’approche de STOP2030 repose sur la combinaison de deux médicaments préexistants dans une seule tablette, ce que permet d’obtenir un traitement plus efficace et accessible pour les
- [Recursos-pt](https://stop2030.org/pt/recursos-pt/) - Recursos multimédia Explore os materiais disponíveis Vídeo do projeto STOP2030 contado pelos nossos parceiros Os nossos resultados de investigação mais recentes Explore o repositório de publicações 2022202120202022 Gandasegui J, et al. Ivermectin and albendazole coadministration: opportunities for strongyloidiasis control. Lancet Infect Dis. 2022 Jul 15:S1473-3099(22)00369-3. Grau-Pujol B, et al. Single-Nucleotide Polymorphisms in the Beta-Tubulin Gene
- [Ressources](https://stop2030.org/fr/ressources/) - Ressources multimédias Découvrez nos matériaux disponibles Vidéo du projet STOP2030 raconté par nos partenaires. Les derniers résultats de nos recherches Découvrez notre répertoire de publications 2022202120202022 Gandasegui J, et al. Ivermectin and albendazole coadministration: opportunities for strongyloidiasis control. Lancet Infect Dis. 2022 Jul 15:S1473-3099(22)00369-3. Grau-Pujol B, et al. Single-Nucleotide Polymorphisms in the Beta-Tubulin Gene and
- [Recursos](https://stop2030.org/es/recursos/) - Recursos multimedia Explora nuestros materiales disponibles Vídeo del proyecto STOP2030 contado por nuestros colaboradores Nuestros últimos resultados de investigación Explore nuestro repositorio de publicaciones 2022202120202022 Gandasegui J, et al. Ivermectin and albendazole coadministration: opportunities for strongyloidiasis control. Lancet Infect Dis. 2022 Jul 15:S1473-3099(22)00369-3. Grau-Pujol B, et al. Single-Nucleotide Polymorphisms in the Beta-Tubulin Gene and Its
- [Contacto](https://stop2030.org/es/contacto/) - Contáctanos Comunícate con nuestro equipo Recaredo, 3 28002, Madrid (Spain) (+34) 916 50 99 43 mundosano [at] mundosano.org Nombre *Correo electrónico *Mensaje *He leído el texto informativo / I read the informative text Español: Los datos facilitados serán tratados por Fundación Mundo Sano con el fin de atender y dar respuesta a su solicitud, basado
- [Consortium-fr](https://stop2030.org/fr/consortium-fr/) - Rencontrez les partenaires Experts en recherche clinique sur les helminthes Cliquez sur les points pour voir les collaborateurs Cliquez sur les points pour voir les collaborateurs Ghana Service de santé du Ghana (GHS)Kenya Kenya Medical Research Institute (KEMRI)Espagne Laboratorios Liconsa SA (Liconsa)Fundación Mundo Sano (FMS)Fundacion Privada Instituto De Salud Global Barcelona (ISGLOBAL)Suisse Bridges To Development
- [Contexte](https://stop2030.org/fr/contexte/) - Vers intestinaux Un long passé de besoins non satisfaits L'impact sur la santé et sur l'éducation Cinq espèces de vers, un quart de la population mondiale infectée Les infections par des helminthes transmis par le sol (STH) sont considérées comme des maladies tropicales négligées, un groupe de maladies qui touchent les enfants et les adultes
- [Home-fr](https://stop2030.org/fr/home-fr/) - Innover dans le traitement des parasites intestinaux Un partenariat international pour la mise en œuvre d’une nouvelle médicine deux-en-un pour l’helminthiase Le résultat de plus de 5 années de recherche L’histoire derrière notre traitement pour les vers intestinaux Le projet de recherche STOP2030 constitue l'étape finale de notre travail de recherche pour créer un traitement
- [Contexto-es](https://stop2030.org/es/contexto-es/) - Parásitos intestinales Una larga historia de necesidades no satisfechas Impactar en la salud y la educación Cinco especies de parásitos, un cuarto de la población mundial infectada Las infecciones por helmintos transmitidos por el suelo (STH) son consideradas enfermedades tropicales desatendidas, es decir, enfermedades que afectan a niños y adultos en las comunidades más pobres
- [Consórcio](https://stop2030.org/pt/consorcio-2/) - Conheça os parceiros Especialistas clínicos e de investigação em helmintos Click on the pin-points to view the partners Clique nos pontos para ver os parceiros Ghana Ghana Health Service (GHS)Kenya Kenya Medical Research Institute (KEMRI)Spain Laboratorios Liconsa SA (Liconsa)Fundación Mundo Sano (FMS)Fundacion Privada Instituto De Salud Global Barcelona (ISGLOBAL)Switzerland Bridges To Development (Bridges)United Kingdom Wellcome
- [Contexto-pt](https://stop2030.org/pt/contexto-pt/) - Parasitas intestinais Uma longa história de necessidades não atendidas Impacto na saúde e na educação Cinco espécies de parasitas, um quarto da população mundial infetada As infeções helmínticas transmitidas pelo solo (HTS) são consideradas Doenças Tropicais Negligenciadas, um grupo de patologias que afetam crianças e adultos nas comunidades mais pobres do mundo. Existem cinco espécies
- [Projeto](https://stop2030.org/pt/projeto/) - Uma abordagem única ao tratamento da helmintíase Desencadear o poder da conjugação Cinco espécies, dois medicamentos, um comprimido Uma ferramenta acessível e eficiente para controlar a infeção O modelo adotado no STOP2030 consiste em combinar dois medicamentos existentes num único comprimido que permite um tratamento mais eficiente e acessível das infeções helmínticas. Estes dois compostos
- [Home-pt](https://stop2030.org/pt/home-pt/) - Inovar no tratamento contra os parasitas intestinais Uma parceria internacional para lançar um novo medicamento dois-em-um para combater a helmintíase O culminar de mais de 5 anos de investigação A história subjacente ao nosso tratamento contra os parasitas intestinais O projeto de investigação STOP2030 assinala os passos finais do nosso percurso de investigação para criar
- [Sample Page](https://stop2030.org/sample-page/) - UNDER CONSTRUCTION
- [Privacy policy](https://stop2030.org/privacy-policy/) - Privacy policy PRIVACY POLICY (v. English) General This Privacy Policy describes how Mundo Sano Foundation (hereinafter, referred to as “Mundo Sano”) manage and process the information collected from you (the “User”) when navigating through its website https://stop2030.org hereinafter, the “Website”). Please read carefully this Privacy Policy as it contains important information concerning the personal data
- [Noticias](https://stop2030.org/es/noticias/) - Últimas noticias Manténte al día con STOP2030 A landscape analysis of financing pathways for the ivermectin-albendazole FDCMUND0S4N0_5T0P2026-07-16T11:03:00+00:00July 10, 2026|A new paper in PLOS Neglected Tropical Diseases examines how[...]Read More Study maps cost-effectiveness evidence for STH control, supporting community-wide and integrated strategiesMUND0S4N0_5T0P2026-07-16T09:40:43+00:00May 18, 2026|A new scoping review published in PLOS Neglected Tropical Diseases[...]Read More STOP2030 at
- [Noticias-pt](https://stop2030.org/pt/noticias-pt/) - Últimas notícias Mantenha-se atualizado sobre o STOP2030 A landscape analysis of financing pathways for the ivermectin-albendazole FDCMUND0S4N0_5T0P2026-07-16T11:03:00+00:00July 10, 2026|A new paper in PLOS Neglected Tropical Diseases examines how[...]Read More Study maps cost-effectiveness evidence for STH control, supporting community-wide and integrated strategiesMUND0S4N0_5T0P2026-07-16T09:40:43+00:00May 18, 2026|A new scoping review published in PLOS Neglected Tropical Diseases[...]Read More STOP2030 at
- [Cookies policy](https://stop2030.org/cookies-policy/) - Cookies policy COOKIES POLICY (v. Inglés) We inform you that Fundación Mundo Sano (hereinafter, “Mundo Sano”), uses a technology called “Cookies” with the purpose of facilitating users’ (hereinafter, “Users”), navigation and providing them information during their use of our website https://stop2030.org (hereinafter, “Website”). Mundo Sano complies with the applicable electronic communications laws and, in particular,
- [Legal Advice](https://stop2030.org/legal-advice/) - Aviso legal TERMS OF USE (v. English) GENERAL INFORMATION The website https://stop2030.org (hereinafter, the “Website”) owned by Insud Pharma S.L. (“Insud Pharma”) and managed by Fundación Mundo Sano (“Mundo Sano”), foundation with Entity Number G-61911335 and located in Gran Vía Carlos III, 98, Barcelona (Spain), registered in the Registry of Research Foundations, nº: CAT –
- [Actualites](https://stop2030.org/fr/actualites/) - Dernières actualités Restez informé sur STOP2030 A landscape analysis of financing pathways for the ivermectin-albendazole FDCMUND0S4N0_5T0P2026-07-16T11:03:00+00:00July 10, 2026|A new paper in PLOS Neglected Tropical Diseases examines how[...]Read More Study maps cost-effectiveness evidence for STH control, supporting community-wide and integrated strategiesMUND0S4N0_5T0P2026-07-16T09:40:43+00:00May 18, 2026|A new scoping review published in PLOS Neglected Tropical Diseases[...]Read More STOP2030 at the

## Categories

- [Uncategorized](https://stop2030.org/es/category/uncategorized/)
- [Uncategorized](https://stop2030.org/pt/category/uncategorized-pt/)
- [Uncategorized](https://stop2030.org/fr/category/uncategorized-fr/)
- [Uncategorized](https://stop2030.org/category/uncategorized-en/)

## Tags

- [sth](https://stop2030.org/tag/sth/)
- [kemri](https://stop2030.org/tag/kemri/)
- [fixed-dose](https://stop2030.org/tag/fixed-dose/)
- [coformulation](https://stop2030.org/tag/coformulation/)
- [modelling](https://stop2030.org/tag/modelling/)
- [wash](https://stop2030.org/tag/wash/)

## Tags

- [Español](https://stop2030.org/es/)
- [Português](https://stop2030.org/pt/)
- [Français](https://stop2030.org/fr/)
- [English](https://stop2030.org/)